Immutep Faces Class Action Over Alleged Efti Trial Misrepresentations

The complaint filed against the NASDAQ-listed firm centers on claims that Immutep violated the Securities Exchange Act of 1934 by issuing false and misleading statements to the market. Specifically, the suit highlights an SEC Form-K filing from January 30, 2026, in which the company characterized its TACTI-004 trial as showing strong progress. Prosecutors allege that leadership was already aware at the time that the trial would fail to reach its primary efficacy endpoints.

Shareholders seeking to participate in the litigation or those interested in serving as lead plaintiff must act before the July 6, 2026, deadline. The DJS Law Group, which is overseeing the outreach, notes that shareholders do not need to be appointed as lead plaintiffs to recover potential losses. The firm, led by David J. Schwartz, specializes in securities class actions and corporate governance litigation.